Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire)

Clinical Rheumatology

Volumn 35, Issue 5, 2016, Pages 1341-1345

  Fatimah, Nibah ^a,b   Salim, Babur ^a   Nasim, Amjad ^a   Hussain, Kamran ^a   Gul, Harris ^a   Niazi, Sarah ^a  

^a FAUJI FOUNDATION HOSPITAL   (Pakistan)

^b NONE   (Pakistan)

Author keywords

Concomitant DMARD therapy; Methotrexate; Methotrexate dose; Methotrexate intolerance severity score; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE;

ABDOMINAL PAIN; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; FATIGUE; FEMALE; HUMAN; NAUSEA; QUESTIONNAIRE; VOMITING;

ABDOMINAL PAIN; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HUMANS; METHOTREXATE; NAUSEA; SURVEYS AND QUESTIONNAIRES; VOMITING;

EID: 84962714479     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3243-8     Document Type: Article

References (24)

1. Walker BR, Colledge NR, Ralston SH, Penman I (2014) Davidson’s principles and practice of medicine. Elsevier—Health Sciences Division
2. Ajeganova S, Andersson ML, Frostegard J, Hafstrom I (2013) Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 40(12):1958–1966. doi:10.3899/jrheum.130365
3. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4
4. Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S (2014) Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 24(1):33–40. doi:10.3109/14397595.2013.854059
5. Kvien TK, Uhlig T, Odegard S, Heiberg MS (2006) Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 1069:212–222. doi:10.1196/annals.1351.019
6. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265–S272
7. Gramling A, O'Dell JR (2012) Initial management of rheumatoid arthritis. Rheum Dis Clin N Am 38(2):311–325. doi:10.1016/j.rdc.2012.05.003
8. Majithia V, Geraci SA (2007) Rheumatoid arthritis: diagnosis and management. Am J Med 120(11):936–939. doi:10.1016/j.amjmed.2007.04.005
9. Ruderman EM, Nola KM, Ferrell S, Sapir T, Cameron DR (2012) Incorporating the treat-to-target concept in rheumatoid arthritis. J Manag Care Pharm 18(9):1–18
10. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. doi:10.1136/ard.2009.123919
11. Axelsen MB, Eshed I, Horslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Moller J, Junker P, Podenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzboll CG, Jorgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Ostergaard M, group Os (2014) A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204537
12. Wasserman AM (2011) Diagnosis and management of rheumatoid arthritis. Am Fam Physician 84(11):1245–1252
13. Fiehn C (2009) Methotrexate in rheumatology. Z Rheumatol 68(9):747–756. doi:10.1007/s00393-009-0535-2, quiz 757
14. Weekly oral methotrexate therapy: raise awareness of fatal dosing errors (2013). Prescrire international 22 (138):126
15. Chan ES, Cronstein BN (2013) Mechanisms of action of methotrexate. Bull Hosp Jt Dis 71(Suppl 1):S5–S8
16. MacGregor AJ (1995) Classification criteria for rheumatoid arthritis. Baillieres Clin Rheumatol 9(2):287–304
17. Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, Storb BH, Farias MR (2011) Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol 51(1):20–39
18. Braun J (2011) Methotrexate: optimizing the efficacy in rheumatoid arthritis. Therapeutic advances in musculoskeletal disease 3(3):151–158. doi:10.1177/1759720X11408635
19. Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM, Wulffraat NM (2011) High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 63(7):2007–2013. doi:10.1002/art.30367
20. Vezmar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49(1–2):92–104
21. Smolen JS, Aletaha D (2010) The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 28(3 Suppl 59):S18–S27
22. Calasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, Wulffraat NM (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15(6):R217. doi:10.1186/ar4413
23. Babur Salim SA, Bhatti Raza A (2013) Frequency of methotrexate intolerance in juvenile idiopathic arthritis patients (JIA): an experience using methotrexate intolerance severity score (MISS). US Armed Forces Med J
24. Agarwal S, Zaman T, Handa R (2009) Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singap Med J 50(7):686–692